Exercise Magnetic Resonance Imaging in Patients With Obesity Associated Heart Failure
Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Jul 16, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The EXPOSURE study is a clinical trial designed to better understand how certain types of fat around the heart affect its function in people with heart failure that preserves the heart's ability to pump blood (known as HFpEF). Researchers will use specialized imaging (called cardiac magnetic resonance, or CMR) to observe how the heart performs both at rest and during exercise. This study hopes to shed light on how epicardial fat (fat located on the heart) influences heart function and blood flow in the lungs.
To participate in this trial, individuals must be between 65 and 74 years old, show symptoms of heart failure, and meet specific heart function criteria. Participants should be able to perform a bicycle exercise test and must be willing to sign a consent form. However, people who weigh more than 140 kg, have certain heart rhythm issues, or other significant heart problems may not be eligible. Those who join the study can expect to undergo heart imaging tests while they rest and exercise, providing valuable data to advance our understanding of heart failure related to obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Signs and symptoms of HF according to the Europeans Society of Cardiology guideline.
- • 2. LV ejection fraction ≥40%.
- • 3. HFA-PEFF score ≥5 or HFA-PEFF score 2-4 in combination with positive stress test (Figure 1).
- • 4. \>18 years of age
- • 5. In sinus rhythm
- • 6. Able to perform a bicycle exercise test
- • 7. Willing to sign informed consent
- Exclusion Criteria:
- • 1. Body weight \>140 kg
- • 2. Atrial fibrillation or other significant arrhythmia during the assessment
- • 3. Contraindications for CMR (e.g. claustrophobia, implanted cardiac devices)
- • 4. Myocardial infarction, percutaneous coronary intervention or coronary artery bypass graft \<3 months or untreated severe obstructive coronary artery stenosis
- • 5. More than moderate left-sided valve disease.
- • 6. Complex congenital heart disease.
About University Medical Center Groningen
University Medical Center Groningen (UMCG) is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and extensive education in the medical field. As a prominent sponsor of clinical trials, UMCG leverages its multidisciplinary expertise and state-of-the-art facilities to advance medical knowledge and improve therapeutic outcomes. The center fosters collaboration among researchers, healthcare professionals, and industry partners, aiming to translate scientific discoveries into effective treatments that enhance patient health and well-being. With a focus on ethical standards and regulatory compliance, UMCG is dedicated to conducting clinical trials that contribute to the advancement of medicine and the betterment of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Groningen, , Netherlands
Patients applied
Trial Officials
Thomas M Gorter, MD, PhD
Principal Investigator
UMCG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported